nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

14. Diagnostik: Blutbasierte Marker

verfasst von : Heike Bantel, Matthias J. Bahr

Erschienen in: Nicht-alkoholische Fettlebererkrankung

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der Diagnostik der nicht-alkoholischen Fettlebererkrankung (NAFLD) kommt es neben der Klärung der Ätiologie und Bestimmung des Fibrosestadiums auf die frühzeitige Identifikation der Patienten an, bei denen ein signifikanter Progress zu erwarten ist. Insbesondere die Differenzierung zwischen der unkomplizierten Fettleber (NAFL) und der nicht-alkoholischen Steatohepatitis (NASH) ist prognostisch bedeutsam, gelingt aber mit Standardlaborparametern nicht, sondern ist allein histologisch zu erreichen. Der Nachweis von K-18-Fragmenten, die bei der Apoptose von Hepatozyten entstehen, durch den M30-Biomarker stellt einen durch verschiedene Studien gut belegten Weg dar, progressionsgefährdete NAFLD-Patienten frühzeitig im Krankheitsgeschehen zu identifizieren. Dieser Abschnitt entspricht der Zusammenfassung und macht somit keinen Sinn (redundant)

Alexander M, Loomis AK, Fairburn-Beech J et al (2018) Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med 16(1):130PubMedPubMedCentralCrossRef

Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854PubMedCrossRef

Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389–397PubMed

Anty R, Iannelli A, Patouraux S et al (2010) A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 32:1315–1322PubMedCrossRef

Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690PubMedCrossRef

Bantel H, Ruck P, Schulze-Osthoff K (2000) In situ monitoring of caspase activation in hepatobiliary diseases. Cell Death Differ 7:504–505PubMedCrossRef

Bantel H, Lügering A, Heidemann J et al (2004) Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40:1078–1087PubMedCrossRef

Bantel H, John K, Schulze-Osthoff K (2014) Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments. Am J Gastroenterol 109:140–141PubMedCrossRef

Bechmann LP, Kocabayoglu P, Sowa JP et al (2013) Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57:1394–1406PubMedCrossRef

Boursier J, Vergniol J, Guillet A et al (2016) Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 65:570–578PubMedCrossRef

Boursier J, Anty R, Vonghia L et al (2018) Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 47:1387–1396PubMedCrossRef

Canbay A, Feldstein A, Kronenberger B et al (2014) Cytokeratin 18 as marker for non-invasive diagnosis and prognosis of acute and chronic liver diseases. Z Gastroenterol 52:290–295PubMedCrossRef

Canbay A, Kälsch J, Neumann U et al (2019) Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective. PLoS ONE 14:e0214436PubMedPubMedCentralCrossRef

Castéra L, Vilgrain V, Angulo P (2013) Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 10:666–675PubMedCrossRef

Castéra L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1264–1281PubMedCrossRef

Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357PubMedCrossRef

Daniels SJ, Leeming DJ, Eslam M et al (2019) ADAPT: an algorithm incorporating PRO-C3 XE „PRO-C3“ accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 69:1075–1086PubMedCrossRef

Demir M, Lang S, Nierhoff D et al (2013) Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. J Clin Gastroenterol 47:719–726PubMedCrossRef

Diab DL, Yerian L, Schauer P et al (2008) Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6:1249–1254PubMedPubMedCentralCrossRef

Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100PubMedCrossRef

Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557–1565PubMedCrossRef

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402

Ekstedt M, Hagström H, Nasr P et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547–1554PubMedCrossRef

Feldstein AE, Wieckowska A, Lopez AR et al (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50:1072–1078PubMedCrossRef

Feldstein AE, Alkhouri N, De Vito R et al (2013) Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 108:1526–1531PubMedCrossRef

Festi D, Schiumerini R, Marzi L et al (2013) The diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 37:392–400PubMedCrossRef

Fitzpatrick E, Mitry RR, Quaglia A et al (2010) Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. JPGN 15:500–506

Fracanzani AL, Valenti L, Bugianesi E et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48:792–798PubMedCrossRef

Friedman SL, Ratziu V, Harrison SA et al (2018) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67:1754–1767PubMedCrossRef

Gholam PM, Flancbaum L, Machan JT et al (2007) Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102:399–408PubMedCrossRef

Hsu C, Caussy C, Imajo K et al (2019) Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17:630–637PubMedCrossRef

Hyysalo J, Männistö VT, Zhou Y et al (2014) A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60:839–846PubMedCrossRef

Joka D, Wahl K, Moeller S et al (2012) Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 55:455–464PubMedCrossRef

Karsdal MA, Henriksen K, Nielsen MJ et al (2016) Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol 311:G1009–G1017PubMedCrossRef

Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321 PubMedCrossRef

Ku NO, Strnad P, Bantel H et al (2016) Keratins: biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology 64:966–976PubMedCrossRef

Labenz C, Huber Y, Kalliga E et al (2018) Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 48:1109–1116PubMedCrossRef

Leers MP, Kölgen W, Björklund V et al (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567–572PubMedCrossRef

Liebig S, Stoeckmann N, Geier A et al (2019) Multicenter validation study of a diagnostic algorithm to detect NASH and fibrosis in NAFLD patients with low NAFLD fibrosis score or liver stiffness. Clin Transl Gastroenterol 10(8):e00066PubMedPubMedCentralCrossRef

Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease. A Critical Appraisal. J Hepatol 58:1007–1019PubMed

Mofrad P, Contos MJ, Haque M et al (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286–1292PubMedCrossRef

Musso G, Gambino R, Cassader M et al (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617–649PubMedCrossRef

Ong JP, Pitts A, Younossi ZM (2008) Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49:608–612PubMedCrossRef

Palekar NA, Naus R, Larson SP et al (2006) Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26:151–156PubMedCrossRef

Petta S, Vanni E, Bugianesi E et al (2015) The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 35:1566–1573PubMedCrossRef

Poynard T, Ratziu V, Charlotte F et al (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:34PubMedPubMedCentralCrossRef

Roeb E, Steffen HM, Bantel H et al (2015) S2K guideline non-alcoholic fatty liver disease. Z Gastroenterol 53:668–723PubMedCrossRef

Schuppan D, Surabattula R, Wang XY (2018) Determinants of fibrosis progression and regression in NASH. J Hepatol 68:238–250PubMedCrossRef

Shen J, Chan HL, Wong GL et al (2012) Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther 36:1057–1066PubMedCrossRef

Sumida Y, Yoneda M, Hyogo H et al (2011) A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46:257–268PubMedCrossRef

Tamimi TI, Elgouhari HM, Alkhouri N et al (2011) An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54:1224–1229PubMedPubMedCentralCrossRef

Tsutsui M, Tanaka N, Kawakubo M et al (2010) Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol 44:440–447PubMedCrossRef

Vuppalanchi R, Jain AK, Deppe R et al (2014) Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:2121–2130PubMedPubMedCentralCrossRef

Wong VW, Vergniol J, Wong GL et al (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454–462PubMedCrossRef

Wong VW, Vergniol J, Wong GL et al (2012) Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 107:1862–1871PubMedCrossRef

Younes R, Rosso C, Petta S et al (2018) Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver Int 38:715–723PubMedCrossRef

Titel: Diagnostik: Blutbasierte Marker
verfasst von: Heike Bantel
Matthias J. Bahr
Verlag: Springer Berlin Heidelberg
Buch: Nicht-alkoholische Fettlebererkrankung
Print ISBN: 978-3-662-62483-8

Electronic ISBN: 978-3-662-62484-5

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-62484-5_14

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen